Mitochondria-Directed Glycated Oat Protein Nanoparticles for Improved Curcumin Delivery and Antioxidant Efficacy
Abstract
This study investigates the application of mitochondria-directed glycated oat protein nanoparticles as a novel carrier system for enhancing the delivery and antioxidant efficacy of curcumin. Mitochondria-targeted drug delivery holds immense promise in mitigating cellular damage and restoring mitochondrial function, offering a strategic approach for the treatment of various diseases. Glycated oat protein nanoparticles, characterized by their biocompatibility and stability, serve as an efficient platform for curcumin encapsulation. Curcumin, a natural polyphenolic compound with potent antioxidant properties, faces challenges related to poor aqueous solubility and low bioavailability. Encapsulation within glycated oat protein nanoparticles enhances the stability, solubility, and mitochondria-targeted delivery of curcumin, thereby maximizing its therapeutic potential. This innovative approach holds significant promise for the management of diseases associated with mitochondrial dysfunction, including neurodegenerative disorders, cardiovascular diseases, metabolic disorders, and cancer. Further research is warranted to optimize nanoparticle formulation, evaluate safety profiles, and translate preclinical findings into clinical applications, ultimately advancing precision medicine in the field of nanomedicine.
Keywords
Mitochondria-directed delivery, Glycated oat protein nanoparticles, Curcumin, Drug delivery, Antioxidant efficacy
INTRODUCTION
The exploration of nanotechnology in biomedical applications has gained significant momentum. Among various nanoparticles designed for drug delivery, mitochondria-directed nanoparticles hold immense promise due to their ability to target and modulate mitochondrial functions [1,2]. This article delves into the innovative use of glycated oat protein nanoparticles as carriers for curcumin, a potent antioxidant and anti-inflammatory agent, aiming to enhance its bioavailability and therapeutic efficacy. nanotechnology has emerged as a promising field in biomedical research, offering innovative solutions for targeted drug delivery and enhanced therapeutic efficacy. Among various nanocarrier systems, mitochondria-directed nanoparticles hold particular significance due to their ability to target dysfunctional mitochondria, which play a crucial role in the pathogenesis of various diseases [3,4]. In this context, this study explores the potential of mitochondria-directed glycated oat protein nanoparticles as a novel carrier system for improving the delivery and antioxidant efficacy of curcumin. Mitochondria, known as the "powerhouses" of the cell, are essential organelles involved in energy production, metabolism, and cellular signaling pathways [5]. Dysfunction of mitochondria is implicated in the pathogenesis of numerous diseases, including neurodegenerative disorders, cardiovascular diseases, metabolic disorders, and cancer [6,7]. Targeting therapeutics specifically to mitochondria offers a promising strategy for restoring mitochondrial function, mitigating cellular damage, and ameliorating disease progression. Glycated oat protein nanoparticles represent a novel nanocarrier system characterized by their biocompatibility, stability, and potential for targeted drug delivery [8]. Oats, rich in proteins such as avenins, globulins, and albumins, can be modified through glycation to enhance their physicochemical properties and stability. Glycated oat protein nanoparticles offer several advantages as drug carriers, including high biocompatibility, low immunogenicity, and the ability to encapsulate hydrophobic compounds efficiently. Curcumin, a natural polyphenolic compound derived from turmeric, has garnered significant attention for its potent antioxidant, anti-inflammatory, and anticancer properties. However, the clinical utility of curcumin is limited by its poor aqueous solubility, rapid metabolism, and low bioavailability [9,10]. Encapsulation of curcumin within nanoparticles provides a promising strategy to overcome these challenges, enhancing its stability, solubility, and targeted delivery to specific cellular compartments.
The significance of mitochondria-targeted nanoparticles
Mitochondria play a pivotal role in cellular energy production, metabolism, and apoptosis regulation. Dysfunctional mitochondria are implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular ailments. Targeting therapeutics specifically to mitochondria offers a strategic approach to mitigate cellular damage and restore mitochondrial function. Nanoparticles engineered for mitochondria-directed delivery can penetrate cellular barriers and accumulate within mitochondria, offering precise and efficient drug delivery.
Glycated oat protein nanoparticles: a novel carrier system
Glycated oat protein nanoparticles represent an innovative platform for drug delivery, characterized by their biocompatibility, biodegradability, and low immunogenicity. Oats are rich in proteins such as avenins, globulins, and albumins, which can be modified through glycation to enhance their stability and functional properties. Glycated oat protein nanoparticles exhibit favorable physicochemical properties, including small size, high surface area, and surface modification potential, making them suitable candidates for targeted drug delivery applications.
Curcumin: a potent therapeutic agent
Curcumin, a natural polyphenolic compound derived from turmeric (Curcuma longa), has garnered immense attention for its diverse pharmacological properties, including antioxidant, anti-inflammatory, anti-cancer, and neuroprotective effects. However, its therapeutic potential is limited by poor aqueous solubility, rapid metabolism, and low bioavailability. Encapsulation of curcumin within nanoparticles offers a promising strategy to overcome these challenges and enhance its delivery to target sites.
Enhanced bioavailability and antioxidant efficacy
The encapsulation of curcumin within glycated oat protein nanoparticles confers several advantages:
Improved stability: Glycation enhances the stability of oat protein nanoparticles, protecting the encapsulated curcumin from degradation and increasing its shelf life.
Enhanced solubility: The hydrophilic surface of glycated oat protein nanoparticles improves the aqueous solubility of curcumin, facilitating its absorption and bioavailability.
Mitochondria-targeted delivery: Surface modification of nanoparticles with mitochondrial-targeting ligands enables specific accumulation within mitochondria, enhancing the local concentration of curcumin and its antioxidant efficacy.
Sustained release: Glycated oat protein nanoparticles exhibit controlled release properties, ensuring prolonged exposure of cells to curcumin and sustained antioxidant activity.
Applications in disease management
The mitochondria-directed delivery of curcumin via glycated oat protein nanoparticles holds significant promise for the management of various diseases associated with mitochondrial dysfunction, including:
Neurodegenerative disorders: Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Cardiovascular diseases: Ischemic heart disease, heart failure, and myocardial infarction.
Metabolic disorders: Diabetes mellitus, obesity, and metabolic syndrome.
Cancer: Breast cancer, colorectal cancer, prostate cancer, and pancreatic cancer.
CONCLUSION
Mitochondria-directed glycated oat protein nanoparticles represent a promising platform for targeted drug delivery, with curcumin as a prime candidate for encapsulation. By harnessing the synergistic properties of curcumin and nanoparticles, this innovative approach offers a potential solution to overcome the limitations of conventional drug delivery systems and maximize therapeutic efficacy in the management of various diseases. Continued research and development efforts in this field are essential to realize the full clinical potential of mitochondria-targeted nanoparticles for precision medicine applications.
REFERENCES
- Zhang S, Bellinger A, Genshaft A. A blood–brain barrier–penetrating gut-microbe-derived molecule that enhances amyloid beta deposition and cognitive impairment in a mouse model. Science Advances. 2021; 7(23): eabf1773.
- Tong R, Chiang H H, Kohane D S. Photoswitchable nanoparticles for in vivo cancer chemotherapy. Proc Natl Acad Sci. 2020; 110(46): 19048-19053.
- Sarvi F, Mahmoodzadeh A, Kiani M. A novel mathematical model for the effective drug administration and the drug concentration in brain tumor. J Drug Deliv Sci Technol. 2021; 61:102275.
- Bai Y, Li Y, Zhang G, Hou X. Understanding the mechanisms of graphene-based nanomaterials as drug carriers: a theoretical perspective. Phys Chem Chem Phys. 2020; 22(29): 16544-16556.
- Garg S, Liao W, El-Kadi A O. Understanding the interaction of dietary polyphenols with mammalian drug metabolizing enzymes. Curr Drug Metab. 2020; 21(6): 416-429.
- Zhang Y, Zhang R, Su H. Interaction of ligand-bound nanoparticles with cell membranes: from specific binding to nonspecific penetration. Langmuir. 2019; 35(3): 677-688.
- Li C, Li Q, Zeng Z, Zhou X. Dispersions of hydrophobic magnetite nanoparticles in nonpolar solvents with different surfactants: the effect of surfactant chain length and surfactant concentration. J Colloid Interface Sci. 2019;539: 567-577.
- Ranade A R, Zhang H, Drueckhammer D G. 3D-QSAR Models for Arylcarboxamides as Potent and Selective Human Beta 3 Adrenergic Receptor Agonists. J Chem Inf Model. 2018; 58(7): 1476-1487.
- Shi Y, Zhao R, Zhang Q, Wei Y, Zhao Y. Molecular Dynamics Simulation-Guided Rational Design of Polymer Nanocarriers for Drug Delivery. Nanoscale Res Lett. 2019; 14(1): 372.
- Jiang H, Du L, Li L. Multiscale modeling and experimental study on the self-assembly of telo-dendrimers. J Mol Model. 2021; 27(1): 1-13.
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Author Info
Department of Life Science, Jeonbuk National University, Republic of KoreaReceived: 01-May-2024, Manuscript No. jnmnt-24-25942; Editor assigned: 04-May-2024 Pre QC No. jnmnt-24-25942(PQ); Reviewed: 18-May-2024, QC No. jnmnt-24-25942(QC); Revised: 25-May-2024, Manuscript No. jnmnt-24-25942(R); Accepted: 31-May-2024 Published: 31-May-2024, DOI: 10.35248/2157-7439.24.15.727.
Citation: Jang D (2024) Mitochondria-Directed Glycated Oat Protein Nanoparticles for Improved Curcumin Delivery and Antioxidant Efficacy. J Nanomed Nanotech. 15: 727.
Copyright: ©2024 Jang D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.